Group 1 - Wangshan Wangshui-B (02630) surged over 14%, reaching a new high, following the announcement of significant antiviral research against Nipah virus by a team including researchers from the Wuhan Institute of Virology and Shanghai Institute of Materia Medica [1] - Zhaoyi Innovation (03986) increased by over 5.6%, with a forecasted revenue of approximately 9.2 billion yuan for 2025, representing a year-on-year growth of about 25%, and a projected net profit of around 1.61 billion yuan, up 46% [1] - Youran Dairy (09858) rose over 4% after completing a placement of 299.25 million shares at a price of 3.92 HKD per share [1] Group 2 - Yijun Group Holdings (02442) experienced a decline of over 39%, despite a previous surge of 4.4 times since its relisting on December 3, 2022 [2] - Alibaba-W (09988) saw a rise of 1.82% after the launch of its Qwen3-Max-Thinking model, which has over 1 trillion parameters and 36 trillion tokens of pre-training data [2][3] - Junda Co., Ltd. (02865) fell nearly 11%, with a drop of over 30% from its recent peak, following an announcement of a strategic investment in Shanghai Xingyi Xinneng Technology Co., Ltd. [2] Group 3 - WanGuo Data-SW (09698) increased by over 6%, also in response to the launch of Alibaba's Qwen3-Max-Thinking model [3] - MicroPort Scientific Corporation-B (02160) dropped 11% after announcing a proposed share consolidation [3] - Valiant Pharmaceuticals-B (09887) rose nearly 4% after receiving orphan drug designation from the European Commission for its core product [4] Group 4 - AI application software stocks in the US saw significant gains, with Cloudflare (NET.US) up 9.17% and Zoom Communications (ZM.US) up 11.28% [5] - Apple (AAPL.US) rose 2.97% ahead of its Q1 2026 earnings report, with expected revenue growth of 11.3% year-on-year to 138.42 billion USD [5] - Intel (INTC.US) continued its decline, falling 5.72% after a previous drop, with revenue expectations for Q1 2026 significantly below market forecasts [5] Group 5 - Kingsoft Cloud (KC.US) increased by 8.1% following a strategic upgrade of its AI training and deployment platform [6] - Precious metals stocks saw pre-market gains, with First Majestic Silver (AG.US) up 1.1% as gold prices reached historical highs [6]

Core Viewpoint - The company Valiant Pharmaceuticals (维立志博-B, 09887) has seen a significant stock increase following the announcement of its core product, LBL-024, receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1: Product Development - LBL-024 has reached an important milestone in its global development process with the orphan drug designation [1] - The product is currently undergoing Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, showcasing first-in-class (FIC) or best-in-class (BIC) potential [1] Group 2: Regulatory Approvals - On January 14, LBL-024 received Fast Track designation from the U.S. FDA for the treatment of extra-pulmonary neuroendocrine carcinoma [1] - LBL-024 is a bispecific antibody that targets both PD-L1 and 4-1BB, making it the first targeted therapy for 4-1BB receptor in the registration clinical stage for extra-pulmonary neuroendocrine carcinoma [1]

Core Viewpoint - Valiant Bio-B (09887) has seen a significant stock increase, rising over 6% and currently trading at 62.2 HKD, with a transaction volume of 24.4 million HKD, following the announcement of its core product, Valiantxin (LBL-024), receiving orphan drug designation from the European Commission for the treatment of extra-pulmonary neuroendocrine carcinoma (EP-NEC) [1] Group 1 - Valiantxin has reached an important milestone in its global development process, now in Phase II or registration clinical trials for three indications: non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), and EP-NEC, demonstrating first-in-class (FIC) or best-in-class (BIC) potential [1] - On January 14, Valiantxin was granted Fast Track designation by the FDA for the treatment of extra-pulmonary neuroendocrine carcinoma, marking it as the first targeted therapy for the 4-1BB receptor to reach the registration clinical stage globally [1]

（文章来源：每日经济新闻） 每经AI快讯，维立志博-B(09887.HK)早盘重挫后逐步转涨，尾盘涨幅扩大逾5%。截至发稿，维立志博- B涨5%，报58.85港元，成交额4573.08万港元。 ...

维立志博-B(09887)早盘重挫后逐步转涨，尾盘涨幅扩大逾5%。截至发稿，涨5%，报58.85港元，成交 额4573.08万港元。 根据公告，孤儿药认定为维利信提供多项激励措施，包括10年的市场独占权和监管费用减免等。维利信 是一种同时靶向PD-L1与4-1BB的抗体，已在中国的两项临床试验中显示出良好的疗效信号。公司于 2024年4月获得国家药品监督管理局批准开展单臂注册临床试验，并在2024年10月获得治疗后线晚期肺 外神经内分泌癌的突破性疗法认定。 消息面上，维立志博宣布，核心产品维利信(LBL-024)获欧盟委员会授予的孤儿药资格认定，用于治疗 肺外神经内分泌癌(EP-NEC)。这是维利信全球开发进程中又一个重要里程碑，目前，维利信已在非小 细胞肺癌(NSCLC)、小细胞肺癌(SCLC)和EP-NEC三个适应症的二期或注册性临床试验中展示出全球首 创(FIC)或同类最优(BIC)潜力 ...

根据公告，孤儿药认定为维利信提供多项激励措施，包括10年的市场独占权和监管费用减免等。维利信 是一种同时靶向PD-L1与4-1BB的抗体，已在中国的两项临床试验中显示出良好的疗效信号。公司于 2024年4月获得国家药品监督管理局批准开展单臂注册临床试验，并在2024年10月获得治疗后线晚期肺 外神经内分泌癌的突破性疗法认定。 消息面上，维立志博宣布，核心产品维利信(LBL-024)获欧盟委员会授予的孤儿药资格认定，用于治疗 肺外神经内分泌癌(EP-NEC)。这是维利信全球开发进程中又一个重要里程碑，目前，维利信已在非小 细胞肺癌(NSCLC)、小细胞肺癌(SCLC)和EP-NEC三个适应症的二期或注册性临床试验中展示出全球首 创(FIC)或同类最优(BIC)潜力 智通财经APP获悉，维立志博-B(09887)早盘重挫后逐步转涨，尾盘涨幅扩大逾5%。截至发稿，涨5%， 报58.85港元，成交额4573.08万港元。 ...

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, currently trading at 55.2 HKD with a transaction volume of 18.0035 million HKD, following the announcement of orphan drug designation for its dual-specific antibody, Viligene (Oparatuzumab, LBL-024) for the treatment of pulmonary neuroendocrine carcinoma by the European Commission [1] Group 1 - Valiant Pharmaceuticals-B's stock rose by 4.94% to 55.2 HKD as of the report [1] - The company reported a transaction volume of 18.0035 million HKD [1] - The European Commission granted orphan drug designation for Viligene on January 22, 2026, marking a significant milestone in its global development [1] Group 2 - This designation follows the previous orphan drug recognition by the U.S. Food and Drug Administration (FDA) [1] - The dual-specific antibody Viligene is aimed at treating pulmonary neuroendocrine carcinoma [1] - The orphan drug designation is a critical step in the drug's development process, enhancing its potential marketability and support [1]

Core Viewpoint - The stock of Valiant Pharmaceuticals-B (09887) has increased by over 5%, reaching 55.2 HKD, following the announcement of orphan drug designation for its drug Valiant (Oparatuzumab, LBL-024) by the European Commission [1] Group 1 - On January 22, Valiant Pharmaceuticals-B announced that the European Commission granted orphan drug designation for its PD-L1/4-1BB bispecific antibody, Valiant, for the treatment of pulmonary neuroendocrine carcinoma [1] - This designation is a significant milestone, marking the second orphan drug designation for Valiant after receiving similar recognition from the U.S. Food and Drug Administration (FDA) [1] - The announcement reflects Valiant's progress in its global development efforts [1]

每经AI快讯，维立志博-B(09887.HK)一度涨超5%，截至发稿，涨4.94%，报55.2港元，成交额1800.35万 港元。 （文章来源：每日经济新闻） ...

消息面上，1月22日，维立志博-B发布公告，于2026年1月22日，欧盟委员会(EC)发布关于PD-L1/4-1BB 双特异性抗体维利信™(奥帕替苏米单抗，LBL-024)用于治疗肺外神经内分泌癌获授孤儿药认定的2026 年1月9日委员会执行决定。这是继获得美国食品药品监督管理局(FDA)认定后，维利信™获得的第二项 孤儿药认定，标志着维利信™在全球开发进程中的又一个重要里程碑。 智通财经APP获悉，维立志博-B(09887)涨超5%，截至发稿，涨4.94%，报55.2港元，成交额1800.35万港 元。 ...